1 / 5

ESMO 2011 Lung Cancer Vantage 014 Study

ESMO 2011 Lung Cancer Vantage 014 Study. Authors: Dr. Sunil Verma Date posted: September 28 th , 2011. Vantage 014 Study Vorinostat in Mesothelioma Presented by Dr. Lee Krug from Memorial Sloan-Kettering Hospital at ESMO 2011.

abbott
Download Presentation

ESMO 2011 Lung Cancer Vantage 014 Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ESMO 2011 Lung Cancer Vantage 014 Study Authors: Dr. Sunil Verma Date posted: September 28th, 2011

  2. Vantage 014 StudyVorinostat in Mesothelioma Presented by Dr. Lee Krug from Memorial Sloan-Kettering Hospital at ESMO 2011 • Background: Mesothelioma is a rare cancer subtype but still inflicts between 350-400 Canadians annually. The incidence has been steadily rising and linked to asbestos exposure seen with mining and milling work history. Recent evidence has suggested that treatment with platinums and pemetrexed in the first line setting is associated with improved overall survival. There is no standard second line therapy and overall median survival is less than one year.  • Vorinostat is a Hystone deacetylase (HDAC) inhibitor and previous Phase I study showed some activity in patients with Mesothelioma. The Vantage 014 is the largest study conducted in Mesothelioma to date. 

  3. Vantage 014 Study Treatment A: Voriniostat 300mg orally Twice per day 3 of 7 days in a 3-week cycle  R Treatment B: Placebo Patient Population Patients with advanced pleural mesothelioma who have had up to two lines of previous systemic chemotherapy (one of the lines must have contained platinums and pemetrexed)

  4. The Primary Endpoint of this study was Overall Survival RESULTS Conclusion: There is no improvement in Overall Survival with single agent Voriniostat in patients with mesothelioma

  5. BOTTOM LINE FOR MEDICAL ONCOLOGISTS • This is the largest study conducted in patients with mesothelioma • There was no improvement in survival with the use of Vorinostat in the second/third line setting • Be careful planning a large Phase III study based on results from Phase I study with a few patients (there was no Phase II trial of Vorinostat in mesothelioma)

More Related